Growth Metrics

Veracyte (VCYT) Cost of Revenue (2016 - 2026)

Veracyte's Cost of Revenue history spans 14 years, with the latest figure at $25.9 million for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 4.5% to $25.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $100.2 million, a 4.96% increase, with the full-year FY2025 number at $100.2 million, up 4.96% from a year prior.
  • Cost of Revenue hit $25.9 million in Q4 2025 for Veracyte, up from $24.5 million in the prior quarter.
  • Over the last five years, Cost of Revenue for VCYT hit a ceiling of $26.1 million in Q1 2023 and a floor of $16.3 million in Q1 2021.
  • Historically, Cost of Revenue has averaged $23.7 million across 5 years, with a median of $24.3 million in 2023.
  • Biggest five-year swings in Cost of Revenue: skyrocketed 97.81% in 2021 and later decreased 8.99% in 2024.
  • Tracing VCYT's Cost of Revenue over 5 years: stood at $22.2 million in 2021, then grew by 8.62% to $24.1 million in 2022, then rose by 4.7% to $25.3 million in 2023, then dropped by 1.73% to $24.8 million in 2024, then grew by 4.5% to $25.9 million in 2025.
  • Business Quant data shows Cost of Revenue for VCYT at $25.9 million in Q4 2025, $24.5 million in Q3 2025, and $25.3 million in Q2 2025.